

PTO/SB/08A (01-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION  
DISCLOSURE STATEMENT  
BY APPLICANT**

Sheet 1 of 5

**COMPLETE IF KNOWN**

Application Number	10/732,783
Filing Date	December 10, 2003
First Named Inventor	HONE, et al.
Art Unit	Unassigned 1648
Examiner Name	Unassigned PARKIN, JEFFREY
Attorney Docket Number	4115-122-DIV2

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
J	AA	US-5,997,881		12-07-1999	Powell et al.
	AB	US-5,510,119		04-23-1996	Santus et al.
	AC	US-5,191,072		03-02-1993	Hasegawa et al.
	AD	US-5,593,969		01-14-1997	Kamireddy et al.
	AE	US-5,597,573		01-28-1997	Kamireddy et al.
	AF	US-5,158,939		10-27-1992	Takayama et al.
	AG	US-5,189,674		02-23-1993	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation	
					YES	NO <sup>1</sup>
J	AH	WO 97/08955	03-13-1997			
	AI	WO 91/16449	10-13-1991			
	AJ	JP-A-63010728	01-18-1998			
	AK	WO97/18837	05-29-1997			
	AL	WO94/21292	09-29-1994			
	AM	WO95/23156	08-31-1995			
	AN	WO84/04526	11-22-1984			

Examiner  
signatureDate  
Considered

04/15/06

\*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

<sup>1</sup> All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. §1.98(a)(3)(i), according to MPEP 609 III A(3).



**INFORMATION  
DISCLOSURE STATEMENT  
BY APPLICANT**

Sheet 2 of 5

COMPLETE IF KNOWN

Application Number	10/732,783
Filing Date	December 10, 2003
First Named Inventor	HONE, et al.
Art Unit	<del>Unassigned</del> 1648
Examiner Name	<del>Unassigned</del> PARKIN, JEFFREY
Attorney Docket Number	4115-122-DIV2

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation	
					YES	NO <sup>1</sup>
J	AO	WO92/00101	01-09-1992			
	AP	WO92/06113	04-16-1992			
	AQ	0 668 289 A1	08-23-1995			
	AR	0 536 969 A2	04-14-1993			
	AS	0 437 016 A2	07-17-1991			
	AT	2 220 211 A	01-04-1990			
	AU	WO97/25061	07-17-1997			
	AV					


**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
J	AW	Bernstein, et al., 1991, J. Clinical invest. 88:540	
	AX	Begrasra, et al., 1992, Proc. Natl. Acad. Sci 89:6285	
	AY	Bhat et al., Glyco Biology 2:535-539 (1992)	
	AZ	Bunnell et al., Crit. Care Med. Suppl. 23:147 (1995)	
	BA	Bunnell et al., Crit. Care Med. Suppl. 23:A151 (1995)	
	BB	Chemical Abstracts, Vol. 109, No. 17, 7 November 1988, Abstract No. 163524, "Disaccharide Derivatives as Analgesics"	
	BC	Christ et al., J. Am. Chem. Soc. 116:3637 (1994)	
	BD	Darveau et al., "Ability of Bacteria Associated With Chronic Inflammatory Disease to Stimulate E-Selectin Expression and Promote Neutrophil Adhesion", Infect. And Immun. 63:1311-1317 (1995).	
	BE	Erwin and Munford, J. Biol. Chem. 256:16444 (1990)	
	BF	Fagan et al., J. Immunol. 153:5230 (1994)	

Examiner signature		Date Considered	04/15/06
-----------------------	--	--------------------	----------

\*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

<sup>1</sup> All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. §1.98(a)(3)(i), according to MPEP 609 III A(3).



**INFORMATION  
DISCLOSURE STATEMENT  
BY APPLICANT**

Sheet 3 of 5

*COMPLETE IF KNOWN*

Application Number	10/732,783
Filing Date	December 10, 2003
First Named Inventor	HONE, et al.
Art Unit	<del>Unassigned</del> 1648
Examiner Name	<del>Unassigned</del> PARKER, JEFFREY
Attorney Docket Number	4115-122-DIV2


**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
2	BG	Flexner, C. and C. Hendrix, 1997, "Pharmacology of antiretroviral agents," in AIDS: Biology, Diagnosis, Treatment and Prevention, fourth edition, DeVita, J., V., et al., eds., Lippincott-Raven Publishers, pp. 479-493	
	BH	Friedman et al., "Immunodeficiency of Endotoxins and Nontoxic Derivatives for Normal and Leukemic Immunocytes" Advances in Exp. Med. and Biol., Vol. 256, (1990) pp. 525-535.	
	BI	Gait, M. and J. Karn, 1995, "Progress in anti-HIV structure-based drug design," TIBTECH 13(10):430-438	
	BJ	Golenback et al., J. Biol. Chem. 266:19490 (1991)	
	BK	International Search Report dated 17/03/99, for PCT/US98/20264, filed 28/09/98	
	BL	Johnson et al., "Characterization of a Nontoxic Monophosphoryl Lipid A," Review of Infectious Diseases, Vol. 9, No. S5 (1987) pp. S512-S516.	
	BM	Karow et al., J. Bacteriol., 173:741-750 (1991)	
	BN	Karow et al., "Isolation and Characterization of the <i>Escherichia coli</i> msbB Gene, a Multicopy Suppressor of Null Mutations in the High-Temperature Requirement Gene <i>htrB</i> ," J. Bacteriology, 174:702-710 (1992)	
	BO	Karow et al., "The Lethal Phenotype Caused by Null Mutations in the <i>Escherichia coli</i> <i>htrB</i> Gene is Suppressed by Mutations in the <i>accBC</i> Operon, Encoding Two Subunits of Acetyl Coenzyme A Carbohydrate," J. Bacteriol. 174:7407 (1992).	
	BP	Kornbluth et al., J. Exp. Medicine 169:1137 (1989).	
	BQ	Kotani et al., Infect. Immun. 49:225 (1985)	
	BR	Kovach et al., J. Exp. Med. 172:77-84 (1990).	
	BS	Munford and Hall, J. Biol. Chem. 264:15613 (1989).	

Examiner signature		Date Considered	04/15/06
--------------------	--	-----------------	----------

\*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

<sup>2</sup> Applicant is to place a check mark here if English Translation is attached. All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. §1.98(a)(3)(i), according to MPEP 609 III A(3).



# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

Sheet 4 of 5

*COMPLETE IF KNOWN*

Application Number	10/732,783
Filing Date	December 10, 2003
First Named Inventor	HONE, et al.
Art Unit	<del>Unassigned</del> 1648
Examiner Name	<del>Unassigned</del> PARKER, JEFFREY
Attorney Docket Number	4115-122-DIV2

## **NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
J	BT	Neter et al., J. Immunol. 76:377 (1956).	
	BU	Öberg, B. and L. Vrang, 1990, "Screening for new agents," Eur. J. Clin. Microbiol. Infect. Dis. 9(7):466-471	
	BV	Perera et al., Infect. Immun. 61:2015 (1993).	
	BW	Qureshi et al., J. Biol. Chem. 263:5502 (1988)	
	BX	Qureshi et al., J. Biol. Chem. 266:6532 (1991).	
	BY	Raetz et al., J. Bacteriol. 175:5745-5753 (1993).	
	BZ	Rietschal et al., FASEB J. 8:217-225 (1994).	
	CA	Salimath et al., Eur. J. Biochem. 136:195 (1983)	
	CB	Sica et al., J. Exp. Med. 185:969 (1997).	
	CC	Ulmer et al., Infect Immun. 60(12):5145-5152 (1992).	
	CD	Wang et al., Infect. Immun. 59(12):4655-4664 (1991).	
	CE	Yarchoan, R. and S. Broder, 1992, "Correlations between the <i>in vitro</i> and <i>in vivo</i> activity of anti-HIV agents: implications for future drug development," J. Enzym, Inhib. 6:99-111.	
	(CF)	Cornelis, P. et al., 1992, "Stability, frequency, and multiplicity of transposon insertions in the pyoverdine region in the chromosomes of different fluorescent psuedomonads", J.Gen. Microbiol. 138:1337-1343	
	(CG)	Pries, A., et al., 1992, "Indentification of a lipoamide dehydrogenase gene as a second locus affected in poly(3-hydroxybutyric acid)-leaky mutants of <i>Alcaligenes eutrophus</i> ", FEMS Microbiol. Lett. 97:227-234	
	(CH)	Oberg, B., and L. Vrang, 1990, "Screening for new agents", Eur. J. Clin. Microbiol. Infect. Dis. 9(7):466-471	
(CI)	Yarchoan, R. and S. Broder, 1992 "Correlations between the <i>in vitro</i> and <i>in vivo</i> activity of anti-HIV agents: implications for future drug development", J. Enzym. Inhib. 6:99-111		
(CJ)	Gait, M. and J. Karn, 1995, "Progress in anti-HIV structure-based drug design", TIBTECH 13(10):430-438		

Examiner signature		Date Considered	04/15/06
--------------------	--	-----------------	----------

\*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

2 Applicant is to place a check mark here if English Translation is attached. All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. § 1.98(a)(3)(i), according to MPEP 609 III A(3)



**INFORMATION  
DISCLOSURE STATEMENT  
BY APPLICANT**

Sheet 5 of 5

COMPLETE IF KNOWN

Application Number	10/732,783
Filing Date	December 10, 2003
First Named Inventor	HONE, et al.
Art Unit	<del>Unassigned</del> 1648
Examiner Name	<del>Unassigned</del> PARKER, JEFFERY
Attorney Docket Number	4115-122-DIV2

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	CK	Flexner, C. and C. Hendrix, 1997, "Pharmacology of antiretroviral agents", in AIDS: Biology, Diagnosis, Treatment and Prevention, fourth edition, DeVita, Jr., V. et al., eds., Lippincott-Raven Publishers, pp. 479-493	
	CL	Pomerantz, R.J., et al., 1990, "Lipopolysaccharide is a potent monocyte/macrophage-specific stimulator of human immunodeficiency virus type 1 expression", J. Exp. Med. 172:253-261	
	CM	Moriuchi, H., et al., 2000 "In vitro reactivation of human immunodeficiency virus 1 from latently infected, resting CD4 T cells after bacterial stimulation", J. Infect. Dis. 181(6):2041-4 (abstract provided)	
	CN	Sunshine, M., et al., 1997, "Mutation of the htrB gene in a virulent Salmonella typhimurium strain by intergeneric transduction: strain construction and phenotypic characterization", J. Bacteriol. 179(17):5521-5533	

EXAMINER

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

04/15/06